London

David Wilson

David is Chairman and founding partner of WG Partners and has over 30 years’ experience in the City. Previously David was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. David has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. David currently serves as non executive Director of Bionomics Limited and was previously Senior Independent Director of Optos plc prior to its successful sale of Nikon Corporation for c.$400m as well as a non executive director of BerGenBio AS.

Nigel Barnes

Nigel has over 30 years experience of working in the City having been a Director of Pharmaceutical research at ABN AMRO, First Vice President Merrill Lynch European Healthcare Equity Research and a Partner at Sudbrook Associates, a healthcare corporate advisory business. He has a PhD in pharmacology and has worked in the research laboratories of ICI (AstraZeneca) and Glaxo. In addition, he gained Sales & Marketing experience at Glaxo. Nigel has played an active role in a number of the leading corporate transactions, including a number of the major European sector mergers, IPO’s and capital raises.

Claes Spång

Claes has over 15 years experience of working in the City, most recently as Director of Corporate Finance at Singer Capital Markets. Previously, Claes was an Associate Director at Landsbanki and Bridgewell having joined from Robert W. Baird in 2005. Claes has substantial experience in actively managing and executing both domestic and international corporate transactions including IPOs, capital raises and M&A in the Life Sciences sector. Prior to joining the City Claes was a sergeant in the Swedish armed forces.

Olga Holme

Olga has over 20 years experience in Investment Banking. Before joining WG, she worked with the founders at Piper Jaffray as an Associate Vice President, Corporate Access in Corporate Broking/ECM. Prior to this, she worked at Nomura International as Trade Support in both Emerging Markets and UK Equities as well as being PA to the Head of Equities.

Jeffrey Glushakow

Jeff has over a decade of healthcare and life sciences experience across corporate finance, restructuring and strategy. Prior to joining WG, he worked in BDO’s Life Sciences M&A team where he managed multiple transactions. Jeff previously worked in Deloitte’s Healthcare Restructuring teams in the UK and Australia, after beginning his career in the Corporate Development team at ASX-listed Medibank in Sydney. There he helped lead expansion into Asia and corporate transactions. Jeff also speaks Mandarin.

Robin Stürken

Robin has more than 20 years’ financial advisory experience, primarily in private and public M&A transactions as well as growth capital financings. Prior to joining WG, he was with Healthcare & Life Sciences sector dedicated financial advisory boutique Northridge Advisory for eight years, actively originating and executing numerous transactions in the UK and internationally. Prior to joining Northridge, Robin was with Hawkpoint Partners (now Canaccord Genuity), also for eight years. He began his investment banking career in 1998 in the corporate finance department of HSBC Investment Bank. Robin is a German national and holds a finance degree from London Business School.

Parthiv Patel

Parthiv has extensive financial advisory experience in Healthcare & Life Sciences and has worked with a number of leading UK and international private equity firms in the sector. Prior to joining WG, he worked in Deloitte’s Life Sciences M&A team where he led transactions in the outsourced pharma services and healthcare technology sectors. Parthiv previously was part of the Investment Management and Private Equity Audit team at Deloitte in London where his clients included BT Pension Scheme (Hermes Fund Managers), Apollo Private Equity, Norges Bank and the Kuwaiti Investment Authority. Parthiv is a member of the Institute of Chartered Accountants of England & Wales (ICAEW).

Nigel Birks

Nigel has 16 years of City experience focused on the healthcare industry. He most recently worked for Jefferies in global healthcare sales and prior to that Dresdner Kleinwort where he ran the No 1 Extel ranked healthcare research team. Nigel has significant UK & European healthcare transaction experience and has worked with healthcare investors in the US & Europe throughout his time in the City. Prior to that he was in the pharmaceutical industry for 10 years working at Eli Lilly and then for ZS Associates a Chicago based pure play pharmaceutical consultancy. Nigel completed his MBA in 1992 having spent 10 years in the British Army.

Satheesh Nadarajah

Sat has over 15 years’ experience working in the City, most recently as a partner at Bernstein Autonomous. Prior to that he had also worked in healthcare specialist sales at Bank of America Merrill Lynch, Barclays Capital, Morgan Stanley and Deutsche Bank. He has been voted #1 in Extel, and covered BioPharma, Med-Tech and Services on a global basis for the majority of his career. In that time, he built relationships with global specialist institutional investors across the US, Europe and Asia, and been involved in a number of corporate brokerships, capital raises and IPOs. Prior to joining the investment banking industry, Sat worked in audit at Anderson / Deloitte as well as receiving his undergraduate degree from the University of Cambridge. He is a CFA charterholder.

Erland Sternby

Erland is a healthcare specialist salesman with over 20 years in the City of London, covering pharma, biotech and medtech for investors globally but mainly in the UK and in Europe. He has been top-rated in specialist sales both individually and as part of the #1 pharma team at Dresdner Kleinwort. In recent years his focus has been corporate transactions. Prior to specialist equity sales, Erland started his career as a medical doctor in Sweden. He then joined Astra in clinical research. After a business BSc and an international MBA in France he worked for biotech companies in marketing and business development in Europe. In 1997 he moved into finance as a pharma and biotech analyst with Alfred Berg in Stockholm, before moving to London in 2000.

Sydney

Anthony Brown

Anthony entered the financial services sector on the buyside at Royal Sun Alliance investment management after completing a Ph.D at the Institute of Cancer Research in London. RSAIM became part of F&C via two mergers and during this time Anthony won the Thomson Extel Award as best buyside Biotech analyst of 2005. In 2007 Anthony joined the Abu Dhabi Investment Authority, one of the world’s largest sovereign wealth funds, in London. In 2011 Anthony left financial services to join AstraZeneca working directly for the CFO Simon Lowth before joining the Investor Relations department in 2013. Anthony emigrated to Australia in December and joined WG Partners in early 2015.

Julian Chick

Dr Julian Chick has over 17 years’ C-suite and board experience in healthcare and life sciences as well as five years in investment banking and has also been a healthcare analyst for private equity investors and venture capitalists. Over the past 20 years Julian has been involved in numerous public and private company capital raisings, M&A transactions, company restructurings, business development and licensing transactions and corporate strategic planning. Julian has a PhD in Physiology.

London

WG Partners
85 Gresham Street
London
EC2V 7NQ

Sydney

WG Partners Pty Ltd.
Level 2 Unit 204
111 Harrington Street
Sydney
NSW 2000